6-Methoxy-pyridin-3-ylphenylboronic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-Methoxy-pyridin-3-ylphenylboronic acid
• 英文别名: (6-methoxypyridin-3-yl)oxy-phenylborinic acid
• 化学式: C₁₂H₁₂BNO₃
• 分子量: 229.04
• InChiKey: URBPVQASCIUJGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.86
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  51.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  、 6-bromo-8-chloro-10-methyl-3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one 、 6-Methoxy-pyridin-3-ylphenylboronic acid 生成 8-chloro-6-(6-methoxypyridin-3-yl)-10-methyl-3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one
  参考文献：
  名称：

  Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one

  摘要：

  本发明涉及一般式I的化合物或其药学上可接受的盐，其中R1、R2、R3、X、R和n的定义如本文所述。这些化合物可用于治疗精神分裂症、强迫症人格障碍、重度抑郁症、双相障碍、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗引起的认知功能障碍、唐氏综合症、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑性共济失调、肌萎缩侧索硬化症、多发性硬化症、亨廷顿病、中风、放射治疗、慢性压力、对神经活性药物的滥用，如酒精、鸦片类、甲基苯丙胺、苯环利定和可卡因等。

  公开号：

  US09284321B2

文献信息

• PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150246922A1

  公开（公告）日：2015-09-03

  The present invention relates to compounds of general formula I or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , X, R and n are as defined herein. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及公式I或其药学上可接受的盐的化合物，其中R1、R2、R3、X、R和n的定义如本文所述。这些化合物可用于治疗精神分裂症、强迫症人格障碍、重度抑郁症、双相障碍、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、恐慌障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗引起的认知功能障碍、唐氏综合症、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑性共济失调、肌萎缩性侧索硬化症、多发性硬化症、亨廷顿病、中风、放射治疗、慢性压力、神经活性药物滥用，如酒精、鸦片类、甲基苯丙胺、苯环利定和可卡因。
• Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
  申请人：Hoffmann-La Roche Inc.

  公开号：US09284321B2

  公开（公告）日：2016-03-15

  The present invention relates to compounds of general formula I or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, R and n are as defined herein. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及一般式I的化合物或其药学上可接受的盐，其中R1、R2、R3、X、R和n的定义如本文所述。这些化合物可用于治疗精神分裂症、强迫症人格障碍、重度抑郁症、双相障碍、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、惊恐障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗引起的认知功能障碍、唐氏综合症、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑性共济失调、肌萎缩侧索硬化症、多发性硬化症、亨廷顿病、中风、放射治疗、慢性压力、对神经活性药物的滥用，如酒精、鸦片类、甲基苯丙胺、苯环利定和可卡因等。